LSFAE04:	Listing of Adverse Events Leading to Death; Safety Analysis Set (Study jjcs - core)											
Treatment Group 	Subject ID 	Age (years) / Sex / Race 	Onset Dose (unit) / Day of Last Dosea,b 	Preferred Term / Reported Term 	TE? 	Start Date / Time (Study Dayb) 	End Date / Time (Study Dayb) 	Action Taken With Study Treatment 	Relationship to Study Treatmentc 	Toxicity Grade / Serious 	
Xanomeline Low Dose 	01-701-1211 	76 / F / Other 	10 mg / 37 	SUDDEN DEATH / Sudden Death 	Yes 	14JAN2013 / 00:00 (61) 	14JAN2013 / 23:59 (61) 	Dose Reduced 	Not Related 	1 / Yes 	
Placebo 	01-710-1083 	89 / F / White 	10 mg / 37 	MYOCARDIAL INFARCTION / Myocardial Infarction 	Yes 	02AUG2013 / 00:00 (12) 	02AUG2013 / 23:59 (12) 	Dose Rate Reduced 	Possible 	1 / Yes 	

Key: *=imputed date, day, or duration 	
Key: *=imputed date, day, or duration	
Key: *=imputed date, day, or duration	
Key: *=imputed date, day, or duration	
Key: *=imputed date, day, or duration	
Key: *=imputed date, day, or duration	
Key: *=imputed date, day, or duration	
Key: *=imputed date, day, or duration	
Key: *=imputed date, day, or duration	
Key: *=imputed date, day, or duration	
Key: *=imputed date, day, or duration	
a Study day of last administration of [study treatment] prior to or on AE start date. 	a Study day of last administration of [study treatment] prior to or on AE start date.	a Study day of last administration of [study treatment] prior to or on AE start date.	a Study day of last administration of [study treatment] prior to or on AE start date.	a Study day of last administration of [study treatment] prior to or on AE start date.	a Study day of last administration of [study treatment] prior to or on AE start date.	a Study day of last administration of [study treatment] prior to or on AE start date.	a Study day of last administration of [study treatment] prior to or on AE start date.	a Study day of last administration of [study treatment] prior to or on AE start date.	a Study day of last administration of [study treatment] prior to or on AE start date.	a Study day of last administration of [study treatment] prior to or on AE start date.	
b Study day is relative to [the start of [study treatment]]. 	b Study day is relative to [the start of [study treatment]].	b Study day is relative to [the start of [study treatment]].	b Study day is relative to [the start of [study treatment]].	b Study day is relative to [the start of [study treatment]].	b Study day is relative to [the start of [study treatment]].	b Study day is relative to [the start of [study treatment]].	b Study day is relative to [the start of [study treatment]].	b Study day is relative to [the start of [study treatment]].	b Study day is relative to [the start of [study treatment]].	b Study day is relative to [the start of [study treatment]].	
c Relationship is assessed by the investigator. 	c Relationship is assessed by the investigator.	c Relationship is assessed by the investigator.	c Relationship is assessed by the investigator.	c Relationship is assessed by the investigator.	c Relationship is assessed by the investigator.	c Relationship is assessed by the investigator.	c Relationship is assessed by the investigator.	c Relationship is assessed by the investigator.	c Relationship is assessed by the investigator.	c Relationship is assessed by the investigator.	
Note: Adverse events are coded using MedDRA version 26.0; toxicity grade is evaluated according to NCI-CTCAE version 5.0.. 	: Adverse events are coded using MedDRA version 26; toxicity grade is evaluated according to NCI-CTCAE version 5..	: Adverse events are coded using MedDRA version 26; toxicity grade is evaluated according to NCI-CTCAE version 5..	: Adverse events are coded using MedDRA version 26; toxicity grade is evaluated according to NCI-CTCAE version 5..	: Adverse events are coded using MedDRA version 26; toxicity grade is evaluated according to NCI-CTCAE version 5..	: Adverse events are coded using MedDRA version 26; toxicity grade is evaluated according to NCI-CTCAE version 5..	: Adverse events are coded using MedDRA version 26; toxicity grade is evaluated according to NCI-CTCAE version 5..	: Adverse events are coded using MedDRA version 26; toxicity grade is evaluated according to NCI-CTCAE version 5..	: Adverse events are coded using MedDRA version 26; toxicity grade is evaluated according to NCI-CTCAE version 5..	: Adverse events are coded using MedDRA version 26; toxicity grade is evaluated according to NCI-CTCAE version 5..	: Adverse events are coded using MedDRA version 26; toxicity grade is evaluated according to NCI-CTCAE version 5..